SyntheticGestalt to pioneer Enamine’ В-REAL Space of 38 billion compounds leveraging AI to deliver lead compounds faster

June 21, 2024 10:08 AM CEST | By EIN Presswire
 SyntheticGestalt to pioneer Enamine’ В-REAL Space of 38 billion compounds leveraging AI to deliver lead compounds faster
Image source: EIN Presswire

KYIV, UKRAINE, June 21, 2024 /EINPresswire.com/ -- SyntheticGestalt, an AI company specializing in the life sciences domain, and Enamine, a pioneer in the creation of ultra-large chemical spaces of highly feasible compounds, announced today a new research program involving the application of AI for novel drug discovery, followed by biological tests of REAL compounds directly at Enamine (B-REAL).

At the beginning of 2024, the partners started collaborating on generating synthetically accessible biologically active compounds with optimized physicochemical and ADME/ Tox properties.

SyntheticGestalt has developed the world's largest molecular-specific AI model using Enamine’s REAL Space of 38 billion compounds. In this program, SyntheticGestalt will predict the activity against selected targets with simultaneous optimization of ADME/ Tox parameters, to search for favourable lead compounds from the REAL space of 38 billion compounds.

In the longer term, the company aims to solve the long-standing problem of AI drug discovery of “high performance on training data but low performance in empirical research.” SyntheticGestalt's efforts were presented at this year's NVIDIA annual conference (see: https://www.nvidia.com/en-us/on-demand/session/gtc24-se62873/).

The developed AI model significantly reduces the drug discovery cycle, and while relying on Enamine’s REAL Space, it offers another immense benefit. With ever-increasing complications in chemical compound logistics and customs formalities, shipping research samples has significantly contributed to drug discovery's sluggish speed and exorbitant cost. Typical collaboration projects involve multiple CROs, which all must be repeatedly served with chemical compounds to work on. The discovery collaborations are suffocated by compounds stuck at customs or delayed by logistics and compound management teams. The compounds synthesized using the B-REAL platform will be immediately subjected to a broad panel of ADME/ Tox, PK and activity tests directly at Enamine in Bienta biology labs. The data will be provided in a time that is shorter than required for shipping compounds alone. Thus, the overall synthesis and test turnaround time will be reduced to 4-6 weeks.

Dr Petro Borysko, Head of Enamine’s biology department Bienta, commented: “We are delighted to contribute our expertise to the largest-ever compound search initiative in Japan. Our biology labs receive compounds from chemistry colleagues within only one day after short registration in our database. There is no need for our partners to deal with unnecessary compound logistics. The early biological data can guide further research quicker.”

Dr Iaroslava Kos, Director of Business Development at Enamine, added: “While our partners are discovering new drug candidates from among 38 billion compounds, Enamine’s B-REAL platform converts virtual hits into tangible results. Within weeks, novel and promising compounds are synthesized and rigorously tested in vitro. This represents the pinnacle of efficiency and reliability in discovery chemistry and our commitment to advancing drug development and reshaping the landscape of pharmaceutical research.”

Kotaro Kamiya, CTO at SyntheticGestalt, commented: “The immense scale of this AI drug discovery initiative, combining SyntheticGestalt’s world-largest model with Enamine’s colossal REAL Space, presents a significant challenge for us. We are deeply grateful for the various support we have received, which has enabled us to embark on this ambitious endeavour. We are confident that the success of this project will pave the way for new possibilities in AI-driven drug research, opening doors to groundbreaking advancements in the field.”

Dr Iaroslava Kos
Enamine Ltd.
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles